Professional development Vacancies

Regarding amendments to the package leaflet of medicinal products containing posaconazole

24.09.2021 1048 views

Taking into account the report of the Pharmacovigilance Risk Assessment Committee (PRAC) based on the analysis of Periodic Safety Update Reports (PSURs) for medicinal products containing posaconazole, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency reached the following scientific conclusions.

In view of the available literature data on the occurrence of hyperkalemia with a close temporal relationship, a plausible pharmacological mechanism, and a positive re-challenge and de-challenge test, where hyperkalemia occurred with the use of posaconazole and all-trans retinoic acid [ATRA] and disappeared upon withdrawal of posaconazole, the PRAC considers it important to monitor adverse effects when ATRA is used in combination with products that inhibit cytochrome P450 enzymes. The PRAC concluded that appropriate changes should be made to the instructions for medical use of medicinal products containing posaconazole.

CHMP agrees with the scientific conclusions of PRAC.

CHMP considers that the benefit-risk balance for medicinal products containing posaconazole (posaconazole) does not change provided that the instructions for medical use are updated with the relevant information.

List of medicinal products containing posaconazole (posaconazole) and authorized for medical use in Ukraine (according to the State Register of Medicinal Products as of 22.09.2021).

To analyze the published information, the applicant must use the original text available at the linkhttps://www.ema.europa.eu/en/documents/variation-report/noxafil-h-c-610-psusa-00002480-202010-epar-assessment-report_en.pdf